Helicobacter pylori infection and circulating ghrelin levels - A systematic review

Chidi V Nweneka1†, Andrew M Prentice1,2†

Abstract

Background: The nature of the association between ghrelin, an orexigenic hormone produced mainly in the stomach, and Helicobacter pylori (H pylori), a bacterium that colonises the stomach, is still controversial. We examined available evidence to determine whether an association exists between the two; and if one exists, in what direction.

Methods: We reviewed original English language studies on humans reporting circulating ghrelin levels in H pylori infected and un-infected participants; and circulating ghrelin levels before and after H pylori eradication. Meta-analyses were conducted for eligible studies by combining study specific estimates using the inverse variance method with weighted average for continuous outcomes in a random effects model.

Results: Seventeen out of 27 papers that reported ghrelin levels in H pylori positive and negative subjects found lower circulating ghrelin levels in H pylori positive subjects; while 10 found no difference. A meta-analysis of 19 studies with a total of 1801 participants showed a significantly higher circulating ghrelin concentration in H pylori negative participants than in H pylori positive participants (Effect estimate (95%CI) = -0.48 (-0.60, -0.36)). However, eradicating H pylori did not have any significant effect on circulating ghrelin levels (Effect estimate (95% CI) = 0.08 (-0.33, 0.16); Test for overall effect: Z = 0.67 (P = 0.5)).

Conclusions: We conclude that circulating ghrelin levels are lower in H pylori infected people compared to those not infected; but the relationship between circulating ghrelin and eradication of H pylori is more complex.

Background

The relationship between ghrelin, a 28-amino acid peptide secreted primarily by the oxyntic cells of the stomach [1] and involved in body mass regulation, and Helicobacter pylori (H pylori), a bacterium that colonises the stomach, has remained controversial. The first report suggesting an association between the two was that by Nwokolo et al [2] who examined the effect of H pylori eradication on plasma ghrelin levels in 12 healthy adult male and female subjects. They reported that eradicating H pylori from the subjects was associated with an increase in plasma ghrelin levels. At about the same time, Gockel et al [3] reported that H pylori had no effect on plasma ghrelin levels in a study of 39 age- and BMI-matched H pylori positive and negative women. Subsequently a number of other papers, including animal studies, have explored this relationship [4-7]. A number of review articles have also appeared exploring this relationship [8,9]; but none of these has been conducted systematically.

Considering the putative role of ghrelin in body mass regulation, understanding this association could help in maximizing its benefits, and also provide further insight into the physiology of appetite and body mass regulation. The objective of this review is to examine available evidence to determine whether or not a relationship exists between ghrelin and H pylori infection; and where one exist, to investigate the direction of the association. Specifically, this review sets out to answer three questions: 1) Is H pylori infection associated with circulating ghrelin levels? 2) what is the effect of eradicating H pylori infection on circulating ghrelin levels? and 3) what is the effect of H pylori infection on ghrelin producing cells in the stomach?
Methods

Literature search strategy and data extraction
A comprehensive search of the scientific literature (Medline (OVID), OvidMedline (R) 1950 - October Week 2 plus In-process & Non-indexed citations, Embase (1980 to 2010 week 41), and ISI Web of Knowledge) was conducted using the search terms “ghrelin AND helicobacter pylori”. The search was repeated several times. The last search was conducted on October 29, 2010. Further searches were conducted using Google scholar; while the bibliography of original and review articles were searched for studies with ghrelin and helicobacter pylori in their titles. Duplicate searches were first removed; thereafter, the abstracts of retrieved articles were reviewed for relevance prior to accessing the full paper. Only English-language primary studies on humans were included provided that the authors assessed at least one of the following: 1) compared circulating ghrelin concentration in H pylori positive and negative subjects; 2) compared the effect of eradicating H pylori on circulating ghrelin levels; or 3) compared gastric ghrelin in H pylori positive and negative subjects or changes in gastric ghrelin after H pylori eradication. Letters in response to published articles, commentaries, and editorials were excluded. Conference abstracts that had not been published as full papers were included where the full abstracts could be retrieved, provided that such conference abstract contained enough information for either the qualitative or the quantitative synthesis. However, where a conference abstract has been published as a full paper, the full paper was retrieved and the conference proceeding excluded.

Efforts were made to contact authors of conference abstracts whose full paper publications could not be traced to inquire if the paper had been published as a full paper and if not, to get further details about the study. Efforts were also made to contact authors of papers where some relevant information was missing to request for the missing information or for further clarifications. We contacted 18 authors [2,6,10-25]; but only nine authors [2,14,18,21-26] responded and provided the needed information. We were unable to contact one author [27].

We also attempted to group the papers reviewed by study teams in other to assess the spread of the papers reviewed. In deciding whether different papers were published by the same research groups, similarity in authorship was examined. Where at least one author contributed to different publications, those publications were deemed to have emanated from the same research group.

Outcomes evaluated
Outcomes evaluated included: differences in circulating ghrelin levels between H pylori positive and negative subjects; changes in circulating ghrelin concentration after H pylori eradication; differences in ghrelin mRNA between H pylori positive and negative subjects; changes in ghrelin mRNA after H pylori eradication; differences in ghrelin immunoreactive cells between H pylori positive and negative subjects; changes in ghrelin immunoreactive cells after cure; correlation between ghrelin immunoreactive cells with severity of H pylori infection; correlation between gastric and plasma ghrelin; correlation between ghrelin mRNA and plasma ghrelin; and correlation between cells and plasma ghrelin.

Data synthesis
The data extracted were classified into three classes: 1) data comparing circulating ghrelin concentration in H pylori positive and negative subjects; 2) data comparing the circulating ghrelin concentration before and after H pylori eradication; and 3) data assessing any of the gastric ghrelin parameters. Each of these classes was supposed to answer a specific question (Table 1). The variables were re-coded in forms that would make analysis easier (Table 2). Table 3 lists the papers excluded from the review and the reasons for their exclusion.

Statistical analysis
Simple proportions were used to determine the frequency of occurrence of each categorical variable considered; and association between different variables assessed using Fisher’s exact chi² test. Continuous variables like sample size and duration of follow-up was initially summarized using medians and inter-quartile ranges and later categorized as shown in Table 2. Multiple logistic regression analysis was used to assess confounding. The descriptive analysis was conducted using Stata version 8 (StataCorp LP, College Station, Texas, USA).

Meta-analysis
We conducted meta-analyses of summary statistics from individual studies that compared circulating ghrelin levels between H pylori positive and H pylori negative subjects; and for studies that compared circulating ghrelin levels before and after eradication of H pylori. For each study, the mean circulating ghrelin concentrations and standard deviations (sd) for the different comparison groups were used to generate standardized mean differences (SMDs) and 95% confidence intervals (95% CI) since different studies used different units to measure ghrelin concentration, and some studies measured plasma ghrelin while others measured serum ghrelin. For studies that reported standard errors of mean, standard deviation was derived using the formula provided in the Cochrane Handbook of clinical reviews: SD = SEM × √N (http://www3.interscience.wiley.com/homepages/106568753/handbook.pdf). Studies that reported only medians and 95% CI or interquartile ranges
(IQR) [2,6] were not included in the meta-analysis. Table 4 lists studies excluded from the meta-analysis and the reasons for their exclusion.

Study specific estimates were combined using the inverse variance method with weighted average for continuous outcomes in a random effects model. Heterogeneity was assessed using the chi-squared method and the I² method described by Higgins et al [28,29]. For studies that reported different sub-groups separately [30-32] those sub-groups were included as separate papers in the meta-analysis. Chuang et al, [30] reported ghrelin levels for males and females separately. While the data for males did not increase the heterogeneity of the studies, inclusion of the data for females introduced significant heterogeneity to the analysis. All the papers that resulted in significant heterogeneity of the studies in the meta-analysis were removed from the meta-analysis. A separate meta-analysis conducted for this sub-group of excluded studies revealed a significant heterogeneity (P=0.0001; I² = 86%) and the effect size was very small and not significant (SMD -0.13 [-0.33, 0.06], Test for overall effect: Z = 1.36 (P = 0.17)). These papers were therefore completely excluded from the meta-analysis and described in a narrative. Sensitivity analysis was conducted to assess the contribution of each study to the pooled estimate by excluding individual studies one at a time and recalculating the pooled SMD estimates for the remaining studies. Funnel plots were used initially to assess publication bias and later confirmed using Begg’s and Egger’s tests. The meta-analyses were conducted using Review Manager Version 5 (RevMan 5; http://www.cc-ims.net/revman/download), while the Begg’s and Egger’s tests were conducted using Stata version 8 after downloading the installation files for the tests from the internet.

Results
Search results
The literature search yielded 1361 papers (404 from databases and 957 from Google Scholar) plus one unpublished paper. After removing duplicate articles, reviews, commentaries and letters (written in response to published articles), 166 papers (including one conference abstract and one unpublished paper) were left. These were further screened using titles and abstract to assess for eligibility, resulting in the exclusion of 106 articles (Figure 1). The full texts of the remaining 60 articles (excluding the conference abstract) were

| Table 1 Research questions explored by the review |
|-----------------------------------------------|
| **Research question** | **Explanatory data** |
| Is *H pylori* infection associated with circulating ghrelin levels? | Data comparing circulating ghrelin concentration in *H pylori* positive and negative subjects |
| What is the effect of eradicating *H pylori* on circulating ghrelin levels? | Data comparing the circulating ghrelin concentration before and after *H pylori* eradication |
| What is the effect of *H pylori* infection on ghrelin expression in the stomach? | Data assessing any of the gastric ghrelin parameters |

| Table 2 Dictionary of variables used in the review |
|-----------------------------------------------|
| **Variable** | **Coding scheme** |
| Study Team | A, B, C etc |
| Design | Cohort, Cross-sectional, Case control, Experimental |
| Healthy | Healthy only, Sick only, Both |
| Region | Asia, Africa, Europe, North America, South America |
| Gender | Male only, Female only, Both |
| Age | Children only, Adults only, Both |
| Number of methods used to assess *H pylori* | One method; two or more methods |
| Type of ghrelin assay used | Commercial RIA, in-house RIA, Commercial ELISA, Commercial EIA |
| Sample storage | -70°C and below; above -70°C |
| Sample type | Serum, Plasma |
| Weight | Normal, Low, Various, High |
| Difference in circulating ghrelin concentration between *H pylori* + & - subjects | Lower, no difference, higher |
| Changes in circulating ghrelin after cure | Increased, decreased, no change |
| Duration of follow-up | 4 weeks & below; Above 4 weeks |
| Sample size | Two categorizations were done: 1) 50 & below, 51-200, 201 and above; 2) Above 20, Below 20 |
retrieved. Twenty-two papers were subsequently dropped from the review (Table 3), and another 11 from the meta-analysis (Table 4).

**Is H pylori infection associated with circulating ghrelin levels?**

Table 5 is an evidence table of studies that compared circulating ghrelin levels in *H pylori* positive and *H pylori* negative individuals. Twenty-six studies compared circulating ghrelin levels between *H pylori* positive and negative subjects. The analysis of one of the studies [30] was stratified by gender, yielding different results; this study was therefore entered into the evidence table as two separate papers with each gender representing one paper, bringing the total number of papers reviewed to 27. One paper [22] was not included in the evidence table because the grouping of the subjects studied did not permit a straight forward

### Table 3 Papers excluded from the review

| Paper | Reason for exclusion |
|-------|----------------------|
| Suzuki et al, 2006 [54] | Did not report ghrelin levels in *H pylori* positive & *H pylori* negative patients |
| Nunes et al, 2006 [27] | Not sufficient information in abstract and authors could not be contacted for further clarifications |
| Campana et al, 2007 [56] | All subjects were *H pylori* negative |
| Isomoto et al, 2005 [52] | Compared only *H pylori* strains |
| Checchi et al, 2007 [10] | Did not compare serum ghrelin levels in *H pylori* positive & *H pylori* negative subjects |
| Wu et al, 2005 [57] | Did not assess ghrelin |
| Shinomiya et al, 2005 [58] | Did not compare the difference in ghrelin between *H pylori* positive & *H pylori* negative subjects |
| Suzuki et al, 2005 [59] | Did not assess ghrelin |
| Sundbom et al, 2007 [60] | Did not assess *H pylori* |
| Huang et al, 2007 [61] | Did not assess *H pylori* |
| Nishizawa et al, 2006 [62] | Did not assess *H pylori* |
| Ando et al, 2006 [63] | Did not assess ghrelin |
| Kempa et al, 2007 [64] | All subjects were *H pylori* negative |
| Ates et al, 2008 [65] | Did not assess *H pylori* |
| Wang et al, 2006 [66] | Did not assess ghrelin |
| Doki et al, 2006 [67] | Did not assess *H pylori* |
| Gao et al, 2008 [68] | Excluded people with *H pylori* |
| Cherian et al, 2009 [69] | Did not assess ghrelin |
| Kebapci et al, 2009 [70] | Did not assess ghrelin |
| Dutta et al, 2009 [71] | Did not assess ghrelin |
| Gen et al, 2010 [72] | Did not assess ghrelin |
| Taniaka-Shintani et al, 2005 [1] | Examined only ghrelin immunoreactive cells |

### Table 4 Papers excluded from the meta-analysis

| Paper | Reason for exclusion |
|-------|----------------------|
| Nwokolo et al, 2003 [2] | Reported median values & 95% CI; also measured integrated ghrelin levels rather than the discrete measurement that other authors used. The authors stated that the median values were used because the sample size was small and the data were skewed |
| Mendez-Sanchez et al, 2007 [49] | Studied ghrelin immuno-reactive cells, did not provide data on plasma ghrelin levels |
| Salles et al, 2006 [19] | Ghrelin values not provided. Only P-values |
| Gao et al, 2009 [15] | Ghrelin values not provided |
| Choe et al, 2007 [6] | Median & IQR provided. Further clarifications not provided by the authors |
| Czesnikiewicz-Guzik et al, 2005 [12] | Insufficient information for meta-analysis |
| Czesnikiewicz-Guzik et al, 2007 [13] | Insufficient information for meta-analysis |
| Masaoka et al [51] | This was a case study with only one subject |
| Stec-Michalska et al, 2009 [24] | Measured only gastric ghrelin |
| Liew et al, 2006 [47] | Assessed only gastric ghrelin |
| Konturek et al, 2006 [17] | The numbers of *H pylori* positive and negative participants were not provided and the authors did not respond to requests for further information. |
comparison of the *H pylori* positive and *H pylori* negative subjects. The paper was therefore reviewed in a separate narrative. Table 6 summarises the characteristics of the studies included in the evidence table. Most of the studies (77%) investigated both males and females, 85% studied only adults and 52% studied sick subjects mainly subjects with gastrointestinal symptoms (64.7%) and Cancer (17.65%). Thirteen (48.2%) of the studies [15,21,30,33-41] were conducted in Asia; 11 (40.7%) [3,11,12,17,19,26,31, 32,42-44] in Europe and three (11.1%) [14,18,45] in North America. Twenty-two percent of the studies reviewed were contributed by one research group alone, while Japan contributed 30% of the papers. More than two-thirds of the studies used radioimmunoassay to measure serum or plasma ghrelin, 55.6% assessed *H pylori* using two or more methods,
| Reference & Country | Study Team | Design | Healthy | Gender | Age | Method of *H pylori* assessment | Ghrelin assay kit | Overnight fast | Sample storage | Sample type | Weight | Sample size | Sample size | Ghrelin levels in Hp+ vs Hp- |
|---------------------|------------|--------|---------|--------|-----|-------------------------------|------------------|----------------|----------------|-------------|--------|-------------|-------------|-----------------------------|
| Kawashima et al, 2009; Japan [38] | A Cohort | Both | Both | Adults | | Serology | Commercial EIA | Yes | -80 | Plasma | Normal | 220 | | Lower |
| Plonka et al, 2006; Poland [32] | B Cohort | Healthy | Both | Both | | Modified UBT plus ELISA | Commercial RIA | Yes | -80 | Serum | | 538 | | Lower |
| Isomoto et al, 2005; Japan [36] | C Cohort | Sick | Both | Adults | | RUT, histology (Giemsa stain) | In-house RIA | Yes | -80 | Plasma | Normal | 81 | | Lower |
| Roper et al, 2008; USA [18] | D Cross-sectional | Healthy | Men | Adults | | serology, histology & RUT or positive culture | Commercial EIA | Yes | -20 | Serum | Normal | 256 | | No Difference |
| Pacifico et al, 2008; Italy [26] | E Cohort | Both | Both | Children | | Culture of gastric specimen or histology + RUT | Commercial RIA | Yes | -70 | Serum | Normal | 85 | | No Difference |
| Gokcel, 2003; Turkey [3] | F Case control | Sick | Women | Adults | | Not stated | Commercial EIA | Yes | Not stated | Plasma | Normal | 39 | | No Difference |
| Plonka et al, 2006; Poland [43] | B Case control | Healthy | Both | Children | | Serology and UBT | Commercial RIA | Yes | -80 | Serum | Various | 287 | | Lower |
| Shiotani et al, 2005; Japan [21] | G Case control | Healthy | Both | Adults | | Detection of HP IgG ab in the urine | Commercial ELISA | Yes | Not stated | Serum | Various | 132 | | Lower |
| Osawa et al, 2005; Japan [40] | C Case control | Sick | Men | Adults | | Culture & histology | In-house RIA | Yes | -30 | Plasma | Normal | 160 | | Lower |
| Chuang et al*, 2009; Taiwan [30] | H Cross-sectional | Sick | Men | Adults | | Not described | Commercial RIA | Yes | -72 | Plasma | low to normal | 145 | | Lower |
| Chuang et al*, 2009; Taiwan [30] | H Cross-sectional | Sick | Women | Adults | | Not described | Commercial RIA | Yes | -72 | Plasma | low to normal | 196 | | No Difference |
| Alonso et al, 2007; Spain [42] | P Cross-sectional | Sick | Both | Adults | | UBT, histology (Giemsa stain) | Commercial RIA | Yes | -80 | Plasma | Normal | 15 | | Lower |
| Salles et al, 2006; France [19] | I Cross-sectional | Sick | Both | Adults | | UBT, serology, culture, histology & PCR | Commercial RIA | Yes | -80 | Plasma | low to normal | 62 | | Lower |
| Jun et al, 2007; Korea [37] | J Cross-sectional | Sick | Both | Adults | | RUT, histology (Giemsa stain) | Commercial RIA | Yes | -70 | Plasma | Normal | 63 | | No Difference |
| D'Onghia et al, 2007; Italy [31] | K Case control | Both | Both | Adults | | ELISA | Commercial RIA | Yes | -20 | Serum | Various | 79 | | Lower |
| Gao et al, 2009; China [15] | L Case control | Healthy | Both | Adults | | Serology & UBT. | Commercial RIA | Yes | -80 | Plasma | Normal | 100 | | Lower |
| Isomoto et al, 2005; Japan [35] | C Cross-sectional | Sick | Both | Adults | | Anti-IgG antibody, 13C-UBT, or RUT | In-house RIA | Yes | -80 | Plasma | Normal | 89 | | Lower |
| Isomoto et al, 2005; Japan [41] | C Cross-sectional | Sick | Both | Adults | | Serology, UBT or RUT | In-house RIA | Yes | -80 | Plasma | Normal | 249 | | Lower |
| An et al, 2007; Korea [33] | Q Cohort | Sick | Both | Adults | | Not stated | Commercial ELISA | Yes | -70 | Plasma | Normal | 41 | | No difference |
| Nishi et al, 2005; Japan [39] | C Cross-sectional | Both | Both | Adults | | Serology & UBT | In-house RIA | Yes | -80 | Plasma | Normal | 74 | | Lower |
| Czesnikiewicz-Guzik et al, 2005; Poland [12] | B Cross-sectional | Healthy | Women | Adults | | UBT | Not stated | Not stated | Not stated | Serum | Not Stated | 100 | | Lower |
| Study                        | Country/Treatment | Design | Group   | Group | Method            | Species | Analyte | Cut-off | Assay | Phase | Category | Age | Gender | Comparison | Results |
|-----------------------------|-------------------|--------|---------|-------|-------------------|---------|---------|---------|-------|-------|----------|------|--------|------------|---------|
| Konturek et al, 2006; Poland | B Cross-sectional | Healthy | Both    | Both  | UBT & serology    | Human RIA| Yes     | -80     | Serum | Not Stated | 180  | Lower  |            |         |
| Cindoruk et al, 2007; Turkey | M Cohort          | Sick    | Both    | Adults| Either histology or UBT | RIA    | Yes     | -80     | Plasma | Normal | 50      | No Difference |     |
| Isomoto et al, 2004; Japan   | C Cohort          | Sick    | Both    | Adults| Serology          | Commercial RIA | Yes     | -80     | Plasma | Normal | 68      | Lower  |         |            |         |
| de Martel, 2007; USA         | N Case control    | Sick    | Both    | Adults| In-house ELISA    | Commercial ELISA | Yes     | -80     | Serum | Various | 110     | No Difference |     |
| Shak et al, 2008, USA        | R Cohort          | Healthy | Both    | Adults| Serology          | Commercial EIA | Yes     | -20     | Plasma | Obese   | 24      | No difference |     |
| Uzzan et al, 2007 [44]       | S Cohort          | Healthy | Both    | Adults| Histology         | Commercial RIA | Yes     | Not stated | Serum | Obese   | 13      | No difference |     |

* These are from the same paper reporting the same study but were separated because the analysis was stratified by gender and the results for males and females were completely different; hence the decision to separate them.
and in all the studies except one, samples were collected after overnight fast. All comparisons were based on the pre-meal ghrelin levels. In most of the studies (70.4%), the samples were stored at a temperature of -70°C or below until analysed; ghrelin was measured in plasma samples in 63% of the studies, while the participants were of normal weight in 58% of the studies. The sample sizes for the different studies ranged from 13 to 538 (median: 89; IQR: 62, 180).

Overall, 17 studies (63%) reported that circulating ghrelin concentrations were lower in *H pylori* positive subjects. Ten studies from Asia (76.9%) and seven from Europe (63.6%) found that circulating ghrelin levels in *H pylori* positive subjects were lower compared to *H pylori* negative subjects. The rest of the studies, including the three from the USA did not find any difference between *H pylori* positive and negative subjects. There was a weak association between the region of the world where the study was conducted and the finding of a lower circulating ghrelin level in *H pylori* positive subjects compared to *H pylori* negative subjects (Fisher’s exact test = 0.07). This completely disappeared after controlling for gender, age, health status, type of sample used, storage conditions, BMI, and the sample size.

Zub-Pokrowiecka et al [22] investigated ghrelin changes in the plasma and gastric mucosa among participants with various gastric diseases. Their subjects were divided into four groups - Group 1 had gastric cancer and concomitant *H pylori* infection; group 2 had antral gastritis, duodenal ulcer and *H pylori* infection; group 3 had atrophic gastritis of the fundus and corpus of the stomach but no *H pylori* infection; while group 4 had no gastric lesions and no *H pylori* infection. These researchers reported that the fasting plasma ghrelin concentrations varied among the different groups as follows (in descending order): group 2, group 4, group 1 and group 3.

Meta-analysis

Twenty-one of the 26 studies reviewed in this section qualified for inclusion in the meta-analysis. Of these 21 studies, three studies provided ghrelin values for the different categories of subjects studied. Chuang et al [30] presented their results by gender; D’Onghia et al [31] presented their results according to whether the subjects were healthy controls or had colo-rectal cancer; and Plonka et al [32] presented their results for adults and children separately. Because each of these features could affect the circulating ghrelin concentration, the different categories were entered into the meta-analysis as separate papers bringing the total number of papers included to 24 with a total of 2244 participants. Table 4 lists studies excluded from the meta-analysis. Four papers were subsequently removed from the final analysis because they added significant heterogeneity to the analysis.

| Characteristic                  | n   | n %  |
|--------------------------------|-----|-----|
| Study Design                   |     |     |
| Case control                   | 7   | 25.93|
| Cohort                         | 9   | 33.33|
| Cross-sectional                | 11  | 40.74|
| Gender studied                 |     |     |
| Both                           | 21  | 77.78|
| Men                            | 3   | 11.11|
| Women                          | 3   | 11.11|
| Region                         |     |     |
| Asia                           | 13  | 48.15|
| Europe                         | 11  | 40.74|
| North America                  | 3   | 11.11|
| Health status                  |     |     |
| Both                           | 4   | 14.81|
| Healthy                        | 9   | 33.33|
| Sick                           | 14  | 51.85|
| Age Group                      |     |     |
| Adults                         | 23  | 85.19|
| Both                           | 2   | 7.41 |
| Children                       | 2   | 7.41 |
| Type of Sickness               |     |     |
| Cancer                         | 3   | 17.65|
| GI symptoms                    | 11  | 64.71|
| Others†                        | 3   | 17.64|
| HP assessment methods used     |     |     |
| Not Described                  | 5   | 18.52|
| One                            | 7   | 25.93|
| Two or more                    | 15  | 55.56|
| Assay Type                     |     |     |
| Commercial EIA                 | 4   | 14.81|
| Commercial ELISA               | 3   | 11.11|
| Commercial RIA                 | 14  | 51.85|
| In-house RIA                   | 5   | 18.52|
| Not stated                     | 1   | 3.7  |
| Sample Size                    |     |     |
| 50 and below                   | 6   | 22.22|
| 51-200                         | 16  | 59.26|
| 201 and above                  | 5   | 18.52|
| Sample Storage                 |     |     |
| -70°C and above                | 19  | 70.37|
| Below -70°C                    | 4   | 14.81|
| Not described                  | 4   | 14.81|
| Sample type                    |     |     |
| Plasma                         | 17  | 62.96|
| Serum                          | 10  | 37.04|
| BMI of participants            |     |     |
| Normal                         | 15  | 57.69|
| Not Stated                     | 2   | 7.69 |
| Obese                          | 2   | 7.69 |
| Various                        | 4   | 15.38|
| low to normal                  | 3   | 11.54|

†Others include Crohn’s disease (1), diabetes mellitus (1) and multiple conditions (1).
The analysis showed that circulating ghrelin concentration was significantly lower in *H pylori* positive participants than in *H pylori* negative participants (Effect estimate (95%CI) = -0.48 [-0.60, -0.36]). Figure 2 is a forest plot of SMDs of circulating ghrelin concentration between *H pylori* positive and *H pylori* negative subjects. There was no significant heterogeneity among the studies (Heterogeneity: Chi² = 24.21, df = 19 (P = 0.19); I² = 22%). Examination of the funnel plot (Figure 3) suggests some publication bias but the Egger and Begg’s tests indicated no publication bias (Begg’s test: z = 1.20 (continuity corrected), P = 0.23 (continuity corrected); Egger’s bias coefficient = -59.99, P = 0.116). A sensitivity analysis indicated that all the studies included in the meta-analysis contributed approximately equally to the pooled estimate (Table 7). Three of the studies dropped from the meta-analysis did not find any difference in the circulating ghrelin levels between *H pylori* positive and *H pylori* negative subjects [14,26,30]. However, Plonka et al [32] found a significantly lower circulating ghrelin levels among a group of *H pylori* positive Polish shepherds compared to their *H pylori* negative controls. Adding these four papers (excluded because of heterogeneity) only slightly increased the effect estimate (-0.42 [-0.57, -0.27]) but still showed that *H pylori* infection was associated with a lower circulating ghrelin concentration.

What is the effect of eradicating *H pylori* on circulating ghrelin levels?

Table 8 presents an evidence table of the studies that reported the effect of eradicating *H pylori* on circulating ghrelin levels. Thirteen papers were reviewed 12 of which were cohort studies and one RCT. Five of the 13 studies were conducted in Japan; 3 in Korea (both in Asia) and four in Europe. The only study from Africa was an unpublished paper by our team. Table 9 is a summary of the characteristics of the studies in Table 8. In 11 studies, the subjects fasted overnight, and for 3 hours (between 6am and 9am) in one study, before being bled. Osawa et al [46] did not indicate whether their subjects were fasted or not. The sample sizes varied from 3 to 134; median value was 16 (IQR: 9, 43). The duration of follow-up varied from 4 weeks to 52 weeks (median follow-up time: 4.5 weeks; IQR: 4 weeks, 12 weeks). Jang et al [16] were not clear on the duration of follow-up of their subjects.
In seven studies (53.9%) there was no significant difference in circulating ghrelin levels pre- and post *H. pylori* eradication. Three studies (23.1%) reported an increase above the pre-eradication level while 3 (23.1%) reported a decrease below the pre-eradication levels. Cross tabulation of the following variables with change in circulating ghrelin levels following cure of *H. pylori* infection did not show any association: the age of the participants, the type of sample used, duration of follow-up, sample size, weight of participants, temperature at which the blood samples were stored, the assay kit used to measure circulating ghrelin, the number of methods used to assess *H. pylori*, gender, country and the region where the study was conducted. Although not statistically significant, the circulating ghrelin concentration decreased following *H. pylori* eradication in the two studies that measured ghrelin using serum samples (Fisher’s exact test 0.08). Similarly, the two studies conducted on children found a decrease in circulating ghrelin levels after *H. pylori* cure. However, these two studies on children also utilised serum samples; while all the 11 studies conducted in adults used plasma samples. From this descriptive analysis, there is not sufficient data to make a conclusive statement on the effect of *H. pylori* eradication on circulating ghrelin levels.

**Meta-analysis**

Nine (out of the 13 studies reviewed in this section) were included in a meta-analysis with a total population of 592. The excluded studies are listed in Table 4. The analysis showed that eradicating *H. pylori* does not have any significant effect on circulating ghrelin levels (Effect estimate (95% CI) = -0.08 [-0.33, 0.16]; Test for overall effect: Z = 0.67 (P = 0.5)). Figure 4 is a forest plot of SMDs of circulating ghrelin concentration pre- and post-eradication of *H. pylori*. The funnel plot indicated publication bias (Figure 5).

**What is the effect of *H. pylori* infection on ghrelin expression in the stomach?**

Thirteen studies examined the effects of *H. pylori* infection on gastric ghrelin. This includes six cohort studies [6,36,44,46-48], 2 case-control studies [40,49], four cross-sectional studies [18,19,24,37] and one randomised controlled trial [23]. The participants included sick subjects (7), well subjects (3) and both well and sick subjects (2). Eight studies were conducted in Asia, two in...
France, one each in Poland, Brazil and USA. Ten studies recruited both males and females, and three recruited males only. All the sick participants had gastrointestinal symptoms. Different methods were used to assess 
*H. pylori* infection either alone or in combination: histology (11 studies), culture (3), rapid urease assay (5), serology (3), urea breath test (2) and PCR (4). Ten of the 13 studies were conducted on normal weight subjects, two on obese subjects and one on subjects of different body weights. Due to the different gastric ghrelin parameters assessed, a meta-analysis was not possible.

Five studies assessed gastric ghrelin contents: one found it to be lower in *H. pylori* positive subjects [36], three [6,18,44] found no significant difference between *H. pylori* positive and negative participants, and one [24] found increased levels in *H. pylori* positive participants. Isomoto et al [36] compared gastric ghrelin peptide contents in the endoscopic biopsies from the corpus of 56 *H. pylori* positive and 25 *H. pylori* negative subjects using radio-immunoassay. They reported significantly lower gastric ghrelin content in the *H. pylori* positive subjects than the *H. pylori* negative subjects. Roper et al [18] studied 216 adult males of normal BMI presenting for routine endoscopy consisting of 120 *H. pylori* positive and 96 *H. pylori* negative subjects. Although they did not find any significant difference in the gastric ghrelin levels between *H. pylori* positive and *H. pylori* negative subjects, they reported a very wide variation in the concentration of ghrelin in the gastric juice (from <80 to 776,000 pg/ml) with the *H. pylori* positive subjects having higher gastric juice ghrelin levels than the *H. pylori* negative subjects. Choe et al [6] did not find any significant difference in the gastric ghrelin levels between *H. pylori* positive and *H. pylori* negative subjects using biopsied tissues.

Four studies examined the expression of ghrelin mRNA in gastric mucosa [19,36,37,40]. Three studies found ghrelin mRNA expression to be lower in *H. pylori* positive subjects than in *H. pylori* negative subjects, while Jun et al [37] found no difference. Five studies assessed the quantity of ghrelin immunoreactive cells in the gastric mucosa [36,40,47-49]; all of which found that *H. pylori* positive subjects had fewer ghrelin-producing cells than in uninfected subjects. However, in the study by Isomoto et al [36], this difference did not achieve statistical significance.

Five studies compared the various gastric ghrelin parameters before and after *H. pylori* eradication [6,23,36,46,48]. Choe et al [6] did not find any significant difference in the ghrelin concentration in the antrum, corpus and fundus pre- and post- *H. pylori* eradication. Lee et al [23] reported a randomized controlled trial on *H. pylori* positive volunteers without peptic ulcer or any other gastrointestinal symptoms in which the treatment group received triple *H. pylori* eradication regimen while the control group did not receive any treatment. These authors reported a significant increase in gastric ghrelin mRNA expression following eradication compared to

| Table 7 Sensitivity analysis of studies included in the meta-analysis |
|--------------------------|-----------------|-----------------|
| Studies excluded          | SMD (95%CI)     | Test for overall effect |
| Alonso et al, 2007        | -0.47 [-0.59, -0.35] | Z = 7.80 (P < 0.000001) |
| An et al, 2007            | -0.49 [-0.61, -0.37] | Z = 7.88 (P < 0.000001) |
| Chuang et al, male, 2009  | -0.48 [-0.61, -0.35] | Z = 7.39 (P < 0.000001) |
| Cindoruk et al, 2007      | -0.49 [-0.61, -0.38] | Z = 8.48 (P < 0.000001) |
| D’Onghia et al, case, 2007| -0.47 [-0.60, -0.35] | Z = 7.64 (P < 0.000001) |
| D’Onghia et al, control, 2007| -0.49 [-0.61, -0.37] | Z = 7.95 (P < 0.000001) |
| Gokcel et al, 2003        | -0.49 [-0.61, -0.36] | Z = 7.84 (P < 0.000001) |
| Isomoto et al, 2004       | -0.46 [-0.57, -0.35] | Z = 7.96 (P < 0.000001) |
| Isomoto et al, 2005a      | -0.47 [-0.60, -0.35] | Z = 7.47 (P < 0.000001) |
| Isomoto et al, 2005b      | -0.47 [-0.59, -0.34] | Z = 7.43 (P < 0.000001) |
| Isomoto et al, 2005c      | -0.48 [-0.61, -0.35] | Z = 7.14 (P < 0.000001) |
| Jun et al, 2007           | -0.49 [-0.61, -0.36] | Z = 7.72 (P < 0.000001) |
| Kawashima et al, 2009     | -0.48 [-0.61, -0.35] | Z = 7.32 (P < 0.000001) |
| Nishi et al, 2005         | -0.49 [-0.59, -0.39] | Z = 9.72 (P < 0.000001) |
| Osawa et al, 2005         | -0.46 [-0.58, -0.34] | Z = 7.45 (P < 0.000001) |
| Plonka et al, ch1, 2006   | -0.46 [-0.58, -0.34] | Z = 7.65 (P < 0.000001) |
| Roper et al, 2008         | -0.51 [-0.63, -0.39] | Z = 8.37 (P < 0.000001) |
| Shak et al, 2008          | -0.48 [-0.60, -0.36] | Z = 7.79 (P < 0.000001) |
| Shiotani et al, 2005      | -0.46 [-0.59, -0.34] | Z = 7.33 (P < 0.000001) |
| Uzzan et al, 2007         | -0.47 [-0.59, -0.35] | Z = 7.76 (P < 0.000001) |
Table 8 Evidence table of studies that examined changes in circulating ghrelin levels following *H pylori* eradication

| Reference & Country | Study Team | Design | Healthy Gender | Age category | HP assess | Ghrelin assay Kit | Sample storage | Sample type | Weight Sample size | Circulating Ghrelin levels after cure | Follow-up (wks) |
|---------------------|------------|--------|-----------------|--------------|-----------|-------------------|----------------|-------------|------------------|--------------------------------------|---------------|
| Nwokolo et al, 2003; UK [2] | A Cohort | Healthy Both Adults | - | Serology and UBT | Commercial RIA | -20 | Plasma | Various | 10 | Increased | 6 |
| Jang et al, 2008; Korea [16] | B Cohort | Sick Both Adults | - | RUT plus histology & confirmed by UBT | Commercial RIA | -70 | Plasma | Normal | 16 | Increased | Not stated |
| Osawa et al, 2006; Japan [46] | C Cohort | Healthy Men Adults | - | Bacterial culture & histology | In-house RIA | Not stated | Plasma | Normal | 134 | Decreased | 12 |
| Czesnikiewicz-Guzik et al, 2007; Poland [13] | D Cohort | Sick Women Adults | - | UBT; culture of saliva & supragingival dental plaques & serology | Commercial RIA | -80 | Plasma | Not stated | 49 | Increased | 4 |
| Lee et al, 2010; Korea [23] | B RCT | Healthy Both Adults | - | RUT, histology (Giemsa stain) | ELISA | -70 | Plasma | Normal | 9 | No difference | 5 |
| Choe et al, 2007; Korea [6] | E Cohort | Sick Both Adults | - | histology & PCR | Commercial ELISA | -70 | Plasma | Normal | 8 | No difference | 4 |
| Pacifico et al, 2008; Italy [26] | F Cohort | Both Children | - | Culture of gastric specimen or histology + RUT | RIA | -70 | Serum | Normal | 22 | Decreased | 52 |
| Nweneka, et al, unpublished; Gambia | G Cohort | Sick Both Children | - | Culture of gastric specimen or histology + RUT | Commercial RIA | -70 | Serum | Low | 3 | Decreased | 4 |
| Isomoto et al, 2005; Japan [36] | C Cohort | Sick Both Adults | - | RUT, histology (Giemsa stain) | In-house RIA | -80 | Plasma | Normal | 43 | No difference | 4 |
| Isomoto et al, 2005; Japan [35] | C Cohort | Sick Both Adults | - | RUT, histology (Giemsa stain) | In-house RIA | -80 | Plasma | Normal | 10 | No difference | 4 |
| Kawashima et al, 2009; Japan [38] | H Cohort | Both Both Adults | - | Serology | Commercial EIA | -80 | Plasma | Normal | 49 | Increased | 23 |
| Cindoruk et al, 2007; Turkey [11] | I Cohort | Sick Both Adults | - | Either histology or UBT | RIA | -80 | Plasma | Normal | 23 | No difference | 12 |
| Isomoto et al, 2004; Japan [34] | C Cohort | Sick Both Adults | - | Serology | Commercial RIA | -80 | Plasma | Normal | 9 | No difference | 4 |
the control group. Osawa et al [46] also reported an increase in ghrelin mRNA expression following *H. pylori* cure. Although Isomoto et al [36] found a tendency towards increase in ghrelin mRNA expression following *H. pylori* eradication in 50 patients with either peptic ulcer disease or gastritis, while in 11 patients who did not respond to eradication therapy, there was no difference in the number of ghrelin immunoreactive cells pre-and post-eradication therapy.

Three studies [36,47,49] found a negative correlation between ghrelin producing cells in the gastrum and the severity of *H. pylori* infection. Gastric ghrelin content and gastric ghrelin mRNA expression were both positively correlated with plasma ghrelin concentration [36,46].

**Discussion**

The potential role of ghrelin in body mass regulation makes understanding its interactions with *Helicobacter pylori*, a highly prevalent gastrointestinal infection, important. To address this issue, we asked three questions: how does *H. pylori* infection affect circulating ghrelin levels; how does eradicating *H. pylori* affect circulating ghrelin; and how does *H. pylori* infection affect gastric ghrelin and ghrelin producing cells.

The results of our analysis has conclusively shown that circulating ghrelin levels are significantly higher in *H. pylori* negative people than in those infected with *H. pylori* (P = 0.00001). Our results also suggest that eradicating *H. pylori* does not have any significant effect on circulating ghrelin. Although there was no significant heterogeneity between the group of studies that compared circulating ghrelin concentrations before and after *H. pylori* eradication, this result should be interpreted with the following caveats in mind: 1) three of the studies [34-36] included in the meta-analysis came from the same research group; and together accounted for 29% of the effect size; 2) the paper by Osawa et al [46] which reported higher ghrelin levels before *H. pylori* eradication compared to the levels after eradication on its own contributed 26.2% of the effect; and 3) the sample sizes of most of the other studies were relatively small. Interestingly, all the smaller studies, except one, found higher circulating ghrelin levels post-eradication. Even among the subjects studied by Osawa et al [46], plasma ghrelin increased in 50 patients and decreased in 84 patients, although the overall effect was a decrease post-eradication. They were however, able to show that pre-eradication elevation of ghrelin was associated with a

| Characteristic                  | n  | %    |
|---------------------------------|----|------|
| Study Design                    |    |      |
| Cohort                          | 12 | 92.31|
| RCT                            | 1  | 7.69 |
| Gender studied                  |    |      |
| Both                            | 11 | 84.62|
| Men                             | 1  | 7.69 |
| Women                           | 1  | 7.69 |
| Region                          |    |      |
| Africa                          | 1  | 7.69 |
| Asia                            | 8  | 61.54|
| Europe                          | 4  | 30.77|
| Health status                   |    |      |
| Both                            | 2  | 15.38|
| Healthy                        | 3  | 23.08|
| Sick                            | 8  | 61.54|
| Age Group                       |    |      |
| Adults                          | 11 | 84.62|
| Children                       | 2  | 15.38|
| Type of Sickness                |    |      |
| GI Symptoms                     | 9  | 90   |
| PEM                             | 1  | 10   |
| HP assessment methods used      |    |      |
| One                            | 3  | 23.08|
| Two or more                     | 10 | 76.92|
| Assay Type                      |    |      |
| ELISA                           | 2  | 15.38|
| Commercial RIA                  | 8  | 61.54|
| In-house RIA                    | 3  | 23.08|
| Sample Size                     |    |      |
| Above 20                        | 6  | 46.15|
| Below 20                        | 7  | 53.85|
| Sample Storage                  |    |      |
| -70°C and below                 | 11 | 84.62|
| Above -70°C                     | 1  | 7.69 |
| Not described                   | 1  | 7.69 |
| Sample type                     |    |      |
| Plasma                          | 11 | 84.62|
| Serum                           | 2  | 15.38|
| BMI of participants             |    |      |
| Normal                          | 10 | 76.92|
| Others                          | 3  | 23.07|
| Duration of follow-up           |    |      |
| 4 weeks & below                 | 6  | 46.15|
| Above 4 weeks                   | 6  | 46.15|
| Not recorded                    | 1  | 7.69 |
| Change in ghrelin after cure    |    |      |
| Decreased                       | 3  | 23.08|
| Increased                       | 3  | 23.08|
| No difference                   | 7  | 53.85|
fall in ghrelin post-eradication. In our unpublished data, we also found that elevated ghrelin concentration pre-eradication was associated with a fall post-eradication. These two observations suggest that in addition to other factors, the pre-eradication ghrelin level determines the direction of response of ghrelin post-eradication.

The heterogeneity of the studies examining the effect of *H pylori* on gastric ghrelin expression as well as the small number of studies that examined different aspects of this relationship did not allow a meta-analysis to be performed. However, the descriptive data suggests that available evidence is still discrepant; although the weight of evidence seems to favour lower ghrelin mRNA and ghrelin immunoreactive cells in association with *H pylori* infection [19,36,40,47-49]. The ultimate effect of *H pylori* on gastric ghrelin appears to be dependent on the duration of infection and the extent of *H pylori*-induced damage to the gastric mucosa. At least three
studies found a negative correlation between number of ghrelin producing cells and the severity of *H pylori* infection [36,47,49].

The close anatomical proximity between the site of *H pylori* infection and the site of ghrelin production might result in the loss of ghrelin producing cells as part of the *H pylori* associated gastritis, causing reduced ghrelin production. However, such effect will not be restricted to *H pylori* infection and could occur in any other condition associated with gastritis. For example, Checchi et al [10] studied 233 patients with autoimmune gastritis (indicated by elevated parietal cell antibody (PCA)) and 211 control subjects, and found that mean serum ghrelin levels in PCA positive patients were significantly lower than in PCA negative patients, similar to the results found in *H pylori* infection by some studies. This decrease remained significant even after excluding patients with *H pylori* infection, suggesting that the *H pylori* infection was not necessarily responsible for the reduction in serum ghrelin. Again, the region of the stomach biopsied could also affect the results. Jang et al [16] reported that after ulcer healing and *H pylori* eradication, there was a significant increase in the levels of ghrelin mRNA. But while corpus ghrelin mRNA increased after cure and *H pylori* eradication, antral ghrelin mRNA decreased, suggesting a differential response by the ghrelin producing cells in the different regions of the stomach. In healthy *H pylori* infected subjects however, Lee et al [23] found a significant increase in fundic ghrelin mRNA after eradication of *H pylori* (P = 0.0002) but no change in the antral ghrelin mRNA (P = 0.5), suggesting a more complex relationship between gastric ghrelin production and *H pylori* infection. Teasing out this relationship will require more rigorous investigation.

If *H pylori* infection is associated with a lower circulating ghrelin, it is biologically plausible that its eradication will be associated with an increase in circulating ghrelin. But if *H pylori* reduces circulating ghrelin by destroying ghrelin producing cells, then the effect of eradicating it on circulating ghrelin would depend on the duration of infection, the amount of damage to ghrelin-producing cells, and the time it takes for these cells to regenerate. Indeed several studies have found a negative correlation between the number of ghrelin producing cells and the severity of gastritis [36,47,49]. And in one study, there was no change in ghrelin levels post-eradication after 4 weeks of follow-up, but the level progressively increased with follow-up, achieving, in some subjects, significant increase after 6 months of follow-up [36]. In contrast, mice infected with *H pylori* for 6-8 months had higher ghrelin levels compared to time-matched controls, which normalised two months post-eradication [50]. However, Masaoka et al [51] did not find any change in circulating ghrelin levels 2 years after successful eradication of *H pylori* in an adult man.

The discrepancy in the response to *H pylori* eradication could also be related to the strain of *H pylori*. Isomoto et al [52] found that strain diversity in *H pylori* was associated with plasma and gastric ghrelin levels in humans. Patients with type I strain (which express the virulence factors cytotoxin-associated gene product (CagA) and Vacuolating cytotoxin A (VacA)) have lower circulating ghrelin levels than those with the less virulent type II strain which does not express the virulence factors. This finding also argues for a possible racial difference in the association between circulating ghrelin levels and *H pylori* infection: in regions where type I strain is dominant, one would expect to see reduced circulating ghrelin levels. While such speculation is attractive, it might not be entirely correct [53]. In this review, the effect of region and country of study on the relationship between *H pylori* and ghrelin was very weak, and appears to be confounded by several other factors.

The underlying clinical condition of the subject might also be affecting the results. Suzuki et al [54] studied plasma ghrelin in patients with peptic ulcer disease. They found that plasma ghrelin levels were significantly higher in patients with duodenal ulcer as well as those with gastric ulcer compared to those with chronic gastritis. Among the subjects that were *H pylori* positive, plasma ghrelin was significantly higher in patients with duodenal or gastric ulcer than in those with non-ulcer chronic gastritis. After treatment for the ulcer (with healing), no significant change was found in the plasma ghrelin levels (i.e. pre-and post eradication levels were similar). Most of the studies reviewed here recruited subjects with varying degrees and types of gastrointestinal pathology. If each of these gastrointestinal diseases affects ghrelin production differently as suggested by Suzuki et al [54], then the discrepancies noted in this review are to be expected. Compensation from other sources of ghrelin production might also explain the various inconsistencies highlighted in this review. For example, Suzuki et al [55] infected Mongolian gerbils with *H pylori* and assessed the plasma and gastric ghrelin levels at 17 and 23 weeks after the infection. They found a significant decrease in gastric ghrelin in the *H pylori* positive gerbils compared to the controls, but also found a significant increase in plasma ghrelin levels in the *H pylori* positive group. This same group also found increased plasma ghrelin and decreased gastric ghrelin levels in IL-1R1 knockout mice [4] suggesting that other sources of ghrelin might have contributed to the increased plasma ghrelin.
Limitations and implications for research and practice
The major limitation of this review is the use of only English language papers, which raises the possibility of some publication bias. Another limitation in conducting this review is that all except one of the papers were observational studies, most of which did not primarily set out to assess the relationship between ghrelin and H pylori; but assessed both parameters in relation to other objectives. Well designed randomised clinical trials are needed to verify the conclusions made by this review. Also, many of the studies included participants with diverse disease conditions whose impacts on ghrelin secretion have not been investigated before. The best approach to solve the riddle of the relationship between ghrelin and helicobacter pylori might be to study otherwise healthy participants with asymptomatic H pylori infection.

Conclusions
From available evidence, circulating ghrelin concentration is lower in people infected with H pylori compared to those not infected with the bacterium. However, a more complex relationship exists between circulating ghrelin levels and eradication of H pylori. This relationship may be modulated by the strain of infecting H pylori, the duration of follow-up, the extent of H pylori-induced gastritis and other underlying pathology. More studies are needed to further elucidate the impact of H pylori eradication on circulating ghrelin concentration.

Acknowledgements
The authors wish to acknowledge all the authors that responded to our inquiries particularly those that provided us with their raw data sets.

Author details
1Nutrition Programme, Medical Research Council Laboratories, The Gambia, P.O. Box 273, Banjul, The Gambia. 2MRC International Nutrition Group, London School of Hygiene & Tropical Medicine, Keppel Street, London, UK.

Authors’ contributions
CVM conceived the paper, conducted the literature search, initial analysis and took lead in the writing. AMP critically reviewed the analysis, and the initial drafts, and participated in writing subsequent drafts. Both authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests. Funding for this study was provided by the UK Medical Research Council.

Received: 16 March 2010 Accepted: 26 January 2011 Published: 26 January 2011

References
1. Tanaka Shintani M, Watanabe M: Distribution of ghrelin-immunoreactive cells in human gastric mucosa: comparison with that of parietal cells. Journal of gastroenterology 2005, 40(4):345-349.
2. Nwokolo CU, Freshwater DA, O'Hare P, Randeva HS: Plasma ghrelin following cure of Helicobacter pylori. Gut 2003, 52(5):637-640.
3. Gekker A, Gumudulu Y, Kayselrud K, Serin E, Cizer B, Ospathin AK, Guvenen N: Helicobacter pylori has no effect on plasma ghrelin levels. European Journal of Endocrinology 2003, 148(4):423-426.
4. Akiko Y, Suzuki H, Masaoka T, Nomura S, Kubayashiki K, Hosoda H, Kangawa K, Hibi T: Enhanced plasma ghrelin levels in Helicobacter pylori-colonized, interleukin-1-receptor type 1-homozygous knockout (IL-1R1/1-) mice. World J Gastroenterol 2005, 11(27):4148-4153.
5. Anania C, Pacifico L, Castronovo A, Neaga M, Ferrara E, Schiavo E, Bonamico M, Chiesa C: Long-term effects of Helicobacter pylori eradication on the levels of circulating ghrelin and leptin concentrations and on body composition in prepubertal children. Helicobacter 2007, 12(4):393-399.
6. Cho YH, Lee JH, Lee HJ, Pak KH, Jin DK, Song SY, Lee JH: Ghrelin Levels in Gastric Mucosa before and after Eradication of Helicobacter pylori. Gut Liver 2007, 1(2):132-137.
7. Choi JY, Hahn KB: [Ghrelin; influences on Helicobacter pylori-associated gastric diseases]. Korean J Gastroenterology 2006, 48(2):75-81.
8. Osawa H: Ghrelin and Helicobacter pylori infection. World J Gastroenterology 2008, 14(11):6327-6333.
9. Weigt J, Maierheiner P: Influence of Helicobacter pylori on gastric regulation of food intake. Curr Clin Nutr Metab Care 2009, 12(5):522-525.
10. Checchi S, Montanaro A, Pasqui L, Ciucci C, Cevenini G, Sestini F, Fioravanti C, Pacini F: Serum ghrelin as a marker of atrophic body gastritis in patients with parietal cell antibodies. Journal of Clinical Endocrinology & Metabolism 2007, 92(11):4346-4351.
11. Cindoruk M, Yerdin I, Deger SM, Karakant K, Ean U, Unal S: Influence of H pylori plasma on ghrelin in patients without atrophic gastritis. World Journal of Gastroenterology 2007, 13(10):1595-1598.
12. Czesnikiewicz-Guzik M, Belanski W, Guzik TJ, Loster B, Konturek Sj: Helicobacter pylori in the oral cavity and its implications for gastric infection, periodontal health, immunology and dyspepsia. J Physiol Pharmacol 2002, 56(Suppl 6):77-89.
13. Czesnikiewicz-Guzik M, Loster B, Belanski W, Guzik TJ, Konturek PC, Zapala J, Konturek SJ: Implications of oral Helicobacter pylori for the outcome of its gastric eradication therapy. Journal of Clinical Gastroenterology 2007, 41(2):145-151.
14. de Martel C, Haggerty TD, Corley DA, Vogelman JH, Orentreich N, Parsonnet J: Serum ghrelin levels and risk of subsequent adenocarcinoma of the esophagus. American Journal of Gastroenterology 2007, 102(6):1166-1172.
15. Gao X, Kang H, Liu X, Duan P, Yang Y, Ma Z: Circulating ghrelin/obestatin ratio in subjects with Helicobacter pylori infection. Nutrition 2009, 25(5):506-511.
16. Jang EJ, Park SW, Park JS, Park SJ, Hahn KB, Paik SY, Sin MK, Lee ES, Oh SW, Park CY, et al: The influence of the eradication of Helicobacter pylori on gastric ghrelin, appetite, and body mass index in patients with peptic ulcer disease. Journal of Gastroenterology and Hepatology 2008, 23(Suppl 2):S278-285.
17. Konturek PC, Czesnikiewicz-Guzik M, Belanski W, Konturek SJ: Involvement of Helicobacter pylori infection in neuro-hormonal control of food intake. Journal of Physiology & Pharmacology 2006, 57(Suppl 5):67-81.
18. Roper J, Francois F, Shae PL, Mourad MS, Pei Z, Olivarres de Perez AZ, Perez-Perez GI, Tseng CH, Blaser MJ: Leptin and ghrelin in relation to Helicobacter pylori status in adult males. Journal of Clinical Endocrinology & Metabolism 2008, 93(6):2350-2357.
19. Salles N, Menard A, Geanes G, Salzmann M, de Ledehingh V, de Mascarel A, Emeriau JP, Lamouliatte H, Megraud F: Effects of Helicobacter pylori infection on gut appetite peptide (leptin, ghrelin) expression in elderly inpatients. Journals of Gerontology Series A-Biological Sciences & Medical Sciences 2006, 61(11):1144-1150.
20. Shinoda T, Futagami S, Hirotaka T, Hone A, Hamamoto T, Ueki N, Kusunoki M, Miyake K, Gudzi K, Tsukui T, et al: Comparison of Gastric Emptying and Plasma Ghrelin Levels in Patients with Functional Dyspepsia and Non-Erosive Reflux Disease. Digestion 2009, 79(2):65-72.
21. Shiotani A, Miyashita T, Uedo N, Ishii H: Helicobacter pylori infection is associated with reduced circulating ghrelin levels independent of body mass index. Helicobacter 2005, 10(3):377-378.
22. Zub-Pokroviecka A, Rembiasz K, Konturek SJ, Rudynska A, Konturek PC, Budzynski P: Ghrelin in diseases of the gastric mucosa associated with Helicobacter pylori infection. Med Sci Monit 2010, 16(10):CR493-500.
23. Lee ES, Yoon YS, Park CY, Kim HS, Um TH, Baik HW, Jang EJ, Lee S, Park HS, Oh SW: Eradication of Helicobacter pylori increases ghrelin mRNA
expression in the gastric mucosa. *Journal of Korean Medical Science* 2010, 25(2):265-271.

24. Stec-Michalska K, Malicki S, Michalski B, Pezczek L, Wisniewska-Jarosinska M, Nawrot T: Gastric ghrelin in relation to gender, stomach topography and Helicobacter pylori in dyspeptic patients. *World Journal of Gastroenterology* 2009, 15(43):5409-5417.

25. Suzuki H, Masaoka T, Hosoda H, Nomura S, Ohtsuka T, Kangawa K, Ishii H, Hibi T: Plasma ghrelin concentration correlates with the levels of serum pepsinogen I and pepsinogen III ratio - A possible novel and non-invasive marker for gastric atrophy. *Hepato-Gastroenterology* 2004, 51(59):1249-1254.

26. Pacifico L, Anania C, Osborn JF, Ferrara E, Schiavo E, Bonamico M, Chiesa C: Long-term effects of Helicobacter pylori eradication on circulating ghrelin and leptin concentrations and body composition in prepubertal children. *European Journal of Endocrinology* 2008, 158(3):323-332.

27. Nunes FA, Alves JS, Diniz MTC, Barbosa AJA: Helicobacter pylori infection and density of gastric ghrelin-producing cells in obese and Nonobese patients. *Heliocobacter* 2006, 11(4):368-368.

28. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. *BMJ* 2003, 327(7414):557-560.

29. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002, 21(15):1593-1598.

30. Chuang CH, Sheu BS, Yang HB, Lee SC, Kao AW, Cheng HC, Chang WL, Yao WJ: Gender difference of circulating ghrelin and leptin concentrations in chronic Helicobacter pylori infection. *Heliocobacter* 2009, 14(1):54-60.

31. D’Onghia V, Leoncini R, Carli R, Santoro A, Giglioni S, Sorbellini F, Marozza G, Sernini A, Campagna S, Marinella E, et al: Circulating ghrelin levels in patients with colorectal cancer: correlation with tumour stage, Helicobacter pylori infection and BMI. *Biomedicine & Pharmacotherapy* 2007, 61(3-4):137-141.

32. Plonka M, Konturek PC, Bielsanski W, Pawlik T, Brzozowski T, Konturek SJ: Relationship between ghrelin and Helicobacter pylori infection in Polish adult shepherds and their children. *Alimentary Pharmacology & Therapeutics* 2006, 24:160-168.

33. Cindoruk M, Yerkin I, Degre SM, Karakan T, Kan E, Unal S: Influence of H pylori on plasma ghrelin in patients without atrophic gastritis. *World J Gastroenterology* 2007, 13(10):1595-1598.

34. Isomoto H, Nakazato M, Ueno H, Date Y, Nishi Y, Mukae H, Mizuta Y, Ohtsuru A, Yamashita S, Kohno S: Low plasma ghrelin levels in patients with Helicobacter pylori-associated gastritis. *American Journal of Medicine* 2004, 116(6):429-432.

35. Isomoto H, Ueno H, Nishi Y, Watanabe E, Nakazato M, Kohno S: Impact of Helicobacter pylori infection on ghrelin and various neuroendocrine hormones in plasma. *World Journal of Gastroenterology* 2005, 11(11):1644-1658.

36. Isomoto H, Ueno H, Saikingaku Zasshi 2005, 15(43):1595-1598.

37. Jun DW, Lee OY, Lee YY, Choi HS, Kim TH, Yoon BC: Changes in plasma ghrelin levels in patients with gastric mucosa-associated lymphoid tissue. *Gastroenterology* 2005, 129(5):1595-1598.

38. Kawashima J, Ohno S, Sakurada T, Takabayashi H, Kudo M, Ro S, Kato S, Yabuki K: Circulating acylated ghrelin levels decreased in accordance with the extent of atrophic gastritis. *Journal of Gastroenterology* 2009, 44(10):1046-1054.

39. Suzuki H, Nishizawa T, Tsuchimoto K, Hibi T: [Helicobacter pylori infected gastric mucosa--inflammation, atrophy and carcinogenesis]. *Nippon Seikagaku Zasshi* 2005, 86(3):453-457.

40. Osawa H, Nakazato M, Date Y, Kita H, Ohtsuka T, Hibi T, Chuzh Y, Shibuya S, Nakanishi M, Ishii H: Impaired production of gastric ghrelin in chronic gastritis associated with Helicobacter pylori. *Journal of Clinical Endocrinology & Metabolism* 2003, 90(10):1-16.

41. Isomoto H, Nishi Y, Ohnita K, Mizuta Y, Kohno S, Ueno H, Nakazato M: The Relationship between Plasma and Gastric Ghrelin Levels and Strain Diversity in Helicobacter pylori Virulence. *Am J Gastroenterol* 2005, 100(6):1425-1427.

42. Alonso N, Granada ML, Salinas I, Reverler JL, Flores L, Ojanguren I, Martinez-Caceres EM, Sanmarti A: Plasma ghrelin concentrations in type 1 diabetic patients with autoimmune atrophic gastritis. *European Journal of Endocrinology* 2007, 157(6):763-769.

43. Plonka M, Bielsanski W, Konturek SJ, Targosz A, Slivowski Z, Dobrzenska M, Karminska A, Site O, Konturek PC, Brzozowski T: Helicobacter pylori infection and serum gastrin, ghrelin and leptin in children of Polish shepherds. *Digestive & Liver Disease* 2006, 38(2):91-97.

44. Uzzan B, Catheline JM, Lagorce C, Bon C, Cohen R, Perret GY: Benamouzin R: Expression of ghrelin in fundus is increased after gastric banding in morbidly obese patients. *Obesity Surgery* 2007, 17(9):1159-1164.

45. Shik JR, Rogers-Perez G, Giordano CT, Fransen E, Garanzis Z, Patterson C, Meinhold E, Fielding GA, Ren C, et al: The Effect of laparoscopic gastric banding surgery on plasma levels of appetite control, insulino tactic, and digestive hormones. *Obesity Surgery* 2008, 18(9):1089-1096.

46. Osawa H, Kita H, Ohnishi H, Nakazato M, Date Y, Bowkust CL, Ishino Y, Watanabe E, Shiya T, Ueno H, et al: Changes in plasma ghrelin levels, gastric ghrelin production, and body weight after Helicobacter pylori cure. *Journal of Gastroenterology* 2006, 41(10):954-961.

47. Llew PL, Lee WJ, Lee YC, Chen WY: Gastric ghrelin expression associated with Helicobacter pylori infection and chronic gastritis in obese patients. *Obes Surg* 2006, 16(5):612-619.

48. Onghia V, Leoncini R, Carli R, Santoro A, Giglioni S, Sorbellini F, Mora JI, Leon-Canales AL, Barredo-Prieto B, Gonzalez-Avila D, Ponciroli-Rodriguez G, Uribe M: Effect of Helicobacter pylori infection on gastric ghrelin expression and body weight. *Revista de Gastroenterología de México* 2007, 72(4):359-364.

49. Carter P, Verdu EF, Foster JA, Lu J, Scharinga A, Koen I, Wang L, Blennnerhassett P, Collins SS: Role of gut-brain axis in persistent abnormal feeding behavior in mice following eradication of Helicobacter pylori infection. *American Journal of Physiology - Regulatory Integrative & Comparative Physiology* 2009, 296(8):R187-194.

50. Masaoka T, Suzuki H, Inada H, Hosoda H, Ohara T, Morishita T, Ishii H, Kangawa K, Hibi T: Long-term strict monitoring of plasma ghrelin and other serological markers of gastric diseases after Helicobacter pylori eradication. *Hepato-Gastroenterology* 2005, 52(61):1-4.

51. Isomoto H, Nishi Y, Ohtsuka K, Mizuta Y, Kohno S, Ueno H, Nakazato M: The Relationship between Plasma and Gastric Ghrelin Levels and Strain Diversity in Helicobacter pylori Virulence. *American Journal of Gastroenterology* 2005, 100(6):1425-1427.

52. Hussein NR, Mohammadi M, Talebkhah Y, Doraghi M, Letter DP, Mohammad MK, Arger RH, Atherton JC: Differences in virulence markers between Helicobacter pylori strains from Iraq and those from Iran: potential importance of regional differences in H. pylori-associated disease. *Journal of clinical microbiology* 2008, 46(5):1774-1779.

53. Suzuki H, Masaoka T, Nomoto Y, Hosoda H, Mori M, Nishizawa T, Minoegishi Y, Kangawa K, Ishii H: Helicobacter pylori infection modifies gastric and plasma ghrelin dynamics in Mongolian gerbils. *Gut* 2004, 53(2):187-194.

54. Campagna D, Nori F, Pagotto U, De Iasio R, Morselli-Labate AM, Pasquali R, Chiesa C: Plasma ghrelin concentrations in type 1 diabetic women: correlation with obesity, gender and weight loss. *Am J Gastroenterol* 2005, 100(6):1425-1427.
60. Sundbom M, Holdstock C, Engstrom E, Karlsson FA: Early changes in ghrelin following Roux-en-Y gastric bypass: Influence of vagal nerve functionality? Obesity Surgery 2007, 17(3):304-310.

61. Huang Q, Fan YZ, Ge BJ, Zhu Q, Tu ZY: Circulating ghrelin in patients with gastric or colorectal cancer. Digestive diseases and sciences 2007, 52(3):803-809.

62. Nishizawa T, Suzuki H, Nomoto Y, Masaoa T, Hosoda H, Mori M, Ohara T, Morishita T, Kangawa K, Hibi T: Enhanced plasma ghrelin levels in patients with functional dyspepsia. Alimentary Pharmacology & Therapeutics 2006, 24:104-110.

63. Ando T, Minami M, Ichiguro K, Maeda O, Watanabe O, Mizuno T, Fujita T, Takahashi H, Noshiro M, Goto H: Changes in biochemical parameters related to atherosclerosis after Helicobacter pylori eradication. Alimentary Pharmacology & Therapeutics 2006, 24:58-64.

64. Kempa A, Krzyzanowska-Swiniarska B, Miazgowski T, Pilar ska K: Not insulin but insulin sensitivity, leptin, and cortisol are major factors regulating serum acylated ghrelin level in healthy women. Journal of Endocrinological Investigation 2007, 30:659-665.

65. Ates Y, Degertekin B, Erdil A, Yaman H, Dagalp K: Serum ghrelin levels in inflammatory bowel disease with relation to disease activity and nutritional status. Digestive diseases and sciences 2008, 53(8):2215-2221.

66. Wang HH, Lee WJ, Liew PL, Yang CS, Liang RJ, Wang W, Lin JT, Wu MS: The influence of Helicobacter pylori infection and corpus gastritis on the postoperative outcomes of laparoscopic vertical banded gastroplasty. Obesity Surgery 2006, 16(3):297-307.

67. Doki Y, Takachi K, Ishikawa O, Miyashiro I, Sasaki Y, Ohigashi H, Hosoda H, Kangawa K, Sasakuma F, et al: Ghrelin reduction after esophageal substitution and its correlation to postoperative body weight loss in esophageal cancer patients. Surgery 2006, 139(6):797-805.

68. Gao XY, Kuang HY, Liu XM, Ma ZB, Nie HJ, Guo H: Plasma obestatin levels in men with chronic atrophic gastritis. Peptides 2008, 29(10):1749-1754.

69. Cherian S, Forbes D, Sanfilippo F, Cook A, Burgner D: Helicobacter pylori, helminth infections and growth: a cross-sectional study in a high prevalence population. Acta Paediatrica 2009, 98(3):860-864.

70. Kebapcilar L, Sari I, Renkal AH, Alacacioglu A, Yuksel A, Ilhan E, Alkan B, Yuksel D, Kozaci DL, Gunay H: The Influence of Helicobacter pylori Eradication on Leptin, Soluble CD40 Ligand, Oxidative Stress and Body Composition in Patients with Peptic Ulcer Disease. Internal Medicine 2009, 48(24):2055-2059.

71. Dutta SK, Atora M, Kir et A, Bashandy H, Gandasas A: Upper Gastrointestinal Symptoms and Associated Disorders in Morbidly Obese Patients: A Prospective Study. Digestive Diseases and Sciences 2009, 54(8):1243-1246.

72. Gen R, Demir M, Araseven H: Effect of Helicobacter pylori Eradication on Insulin Resistance, Serum Lipids and Low-Grade Inflammation. Southern Medical Journal 2010, 103(3):190-196.

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-230X/11/7/prepub

doi:10.1186/1471-230X-11-7
Cite this article as: Nweneka and Prentice: Helicobacter pylori infection and circulating ghrelin levels – A systematic review. BMC Gastroenterology 2011 11:7.

Submit your next manuscript to BioMed Central and take full advantage of:
- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit